ナブリバ・セラピュ―ティクス（NBRV）Nabriva Therapeutics plc - 米国株銘柄紹介 | 米国株を知る場所 nasdaqchart（ナスダックチャート）

NBRVのチャート

NBRVの企業情報

symbol	NBRV
会社名	Nabriva Therapeutics AG （ナブリバ・セラピュ―ティクス）
分野（sector）	Health Care ヘルスケア
産業（industry）	Major Pharmaceuticals
業種	バイオテクノロジ―_メディカルリサ―チ医療関連（Health Care）
概要	事業概要 Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins including both intravenous and oral formulations of its lead product candidate lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications including the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is developing a formulation of lefamulin appropriate for pediatric use. ナブリバ・セラピュ―ティクスはオ―ストリアのバイオ医薬品企業。臨床段階で、主に抗生物質プレウロムチリンに焦点を当て、感染症治療のための抗生物質の研究開発に従事する。市中感染性細菌性肺炎(CABP)の治療向け静脈点滴と経口投与薬を開発、また肺炎以外の疾患に対する有効性を研究。米国内ではペンシルベニア州に拠点を置く。本社はヴィエナ。 Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
本社所在地	Leberstrasse 20 Vienna 1110 AUT
代表者氏名	Daniel D. Burgess ダニエル・D・バージェス
代表者役職名	Independent Chairman of the Supervisory Board
電話番号	―
設立年月日	38626
市場名	NASDAQ National Market System
ipoyear	2015年
従業員数	59人
url	www.nabriva.com
nasdaq_url	https://www.nasdaq.com/symbol/nbrv
adr_tso	―
EBITDA	EBITDA（百万ドル） -73.03200
終値（lastsale）	2.949
時価総額（marketcap）	196061784.891
時価総額	時価総額（百万ドル） 179.50720
売上高	売上高（百万ドル） 10.98800
企業価値(EV)	企業価値(EV)（百万ドル） 104.62120
当期純利益	当期純利益（百万ドル） -75.66100
決算概要	決算概要 BRIEF: For the six months ended 30 June 2018 Nabriva Therapeutics PLC - ADR revenues increased from $2.7M to $8.4M. Net loss increased 4% to $31.1M. Revenues reflect Government grants increase of 39% to $419K. Higher net loss reflects Interest income decrease of 88% to $28K (income) Interest Exp-Net of Capitalized Interest increase from $4K to $11K (expense) Other income (expense) net increase of 2% to $118K (expense).

NBRVのテクニカル分析

NBRVのニュース

7 Stocks to Sell as Banks Melt Down 2023/03/20 22:20:26 InvestorPlace

Peruse the Internet for investment guidance and you’re likely to hear the adage that you shouldn’t consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there’s blood on the streets. To be honest, it sounds bold and daring and something that alpha males do. However, blind adherence to adages can also be extremely dangerous – especially during a banking crisis . While no theoretical upside limit exists with publicly traded securities, historically, what goes up must come down. In many cases – particularly with established blue chips – red ink represents a discounted buying opportunity. However, what goes down doesn’t always come back up. Sometimes, equity shares stay down for good, which is why you must take stocks to sell seriously. To be sure, this topic generates plenty of controversy and hard emotions. We’re talking about money, along with underlying hopes and dreams. I get it. That’s why with this list, I’m combining objective data with analyst opinions.

The Complete Library Of: CorMedix Inc. (NASDAQ:CRMD -0.87%), Nabriva Therapeutics plc (NASDAQ:NBRV 4.19%) 2023/02/25 13:11:29 Stock Equity

CRMD has seen its SMA50 which is now -6.29%. In looking the SMA 200 we see that the stock has seen a 3.98%. NBRV has seen its SMA50 which is … The post The Complete Library Of: CorMedix Inc. (NASDAQ:CRMD -0.87%), Nabriva Therapeutics plc (NASDAQ:NBRV 4.19%) appeared first on Stocks Equity .

NBRV stock on watch as Merck ends distribution agreement (NASDAQ:NBRV) 2023/02/06 13:21:33 Seeking Alpha

Nabriva Therapeutics (NBRV) and Merck (MRK) have ended the deal for U.S. distribution of Sivextro, an antibacterial indicated for certain skin and skin infections. Read the full story here.

Hot Stock’s Highlights: Acorda Therapeutics, Inc. (NASDAQ:ACOR 0.84%), Nabriva Therapeutics plc (NASDAQ:NBRV 1.63%) 2023/02/04 13:47:31 Stock Equity

Acorda Therapeutics, Inc. (NASDAQ:ACOR) with the stream of 0.84% also noticed, India Nabriva Therapeutics plc (NASDAQ:NBRV) encountered a rapid change of 1.63% in the last hour of Friday’s trading session. … The post Hot Stock’s Highlights: Acorda Therapeutics, Inc. (NASDAQ:ACOR 0.84%), Nabriva Therapeutics plc (NASDAQ:NBRV 1.63%) appeared first on Stocks Equity .

Northland Capital Markets Downgrades Nabriva Therapeutics AG to Underperform 2023/01/06 18:12:01 Investing.com

https://www.investing.com/news/pro/northland-capital-markets-downgrades-nabriva-therapeutics-ag-to-underperform-432SI-2975174